Skip to content

Myriad halts HIV maturation inhibitor drug programme

HIV-positive women in clinical trials: A gap in the facts

START… and why the time is now

What happens to people who become HIV positive in prevention trials?

Six existing drug classes now being tested as microbicides

Protease inhibitor monotherapy in clinical practice: valid option for undetectable patients

Rilpivirine proves non-inferior to efavirenz in phase 3 studies

Making sense of randomised trials

d4T dose reduction does not result in poorer treatment outcomes in South African patients